Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation
ABSTRACT Background Chronic spontaneous urticaria (CSU) is a debilitating inflammatory skin disease with a prevalence of approximately 1% of the population. It is characterized by recurrent itchy wheals and/or angioedema for more than 6 weeks without known triggers leading to a high quality of life...
Saved in:
| Main Authors: | Anna Smola, Heike C. Hawerkamp, Péter Oláh, Andreas Kislat, Nicole Duschner, Bernhard Homey, Stephan Meller |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Immunity, Inflammation and Disease |
| Online Access: | https://doi.org/10.1002/iid3.70132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Progress in the application of omalizumab in the treatment of chronic inducible urticaria
by: CHEN Ziyan, et al.
Published: (2024-12-01) -
Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China
by: Yueyang Huang, et al.
Published: (2025-07-01) -
Successful Omalizumab treatment in delayed pressure urticaria as confirmed by stimulation test
by: Cesare Ariasi, et al.
Published: (2025-04-01) -
Results of Therapy Including Omalizumab in Adolescents With Recurrent Urticaria: Retrospective Cohort Study
by: Vera G. Kalugina, et al.
Published: (2019-09-01) -
Omalizumab treatment can increase the serum levels of vitamin D in patients with chronic spontaneous urticaria
by: MENG Zhen, et al.
Published: (2025-03-01)